↓ Skip to main content

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

Overview of attention for article published in BMC Cancer, January 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy
Published in
BMC Cancer, January 2018
DOI 10.1186/s12885-018-4025-2
Pubmed ID
Authors

Shang-Yu Chou, Shao-Lun Yen, Chao-Cheng Huang, Eng-Yen Huang

Abstract

Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expression level in patients with glioblastoma multiforme (GBM) undergoing adjuvant radiotherapy (RT). We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions) > or = 60 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS). Patients with weak expression had a better median survival (27.9 months) than did those with strong expression (10.7 months; p = 0.009). We compared characteristics between weak and strong galectin-1 expression, and only the expression level of galectin-3 showed a correlation. The group with weak galectin-1 expression displayed a 3-year OS of 27.3% and a 3-year cancer-specific survival (CSS) of 27.3%; these values were only 5.9% and 7.6%, respectively, in the group with strong galectin-1 expression (p = 0.009 and 0.020, respectively). Cox regression was used to confirm that the expression level of galectin-1 (weak vs. strong) is a significant factor of OS (p = 0.020) and CSS (p = 0.022). Other parameters, such as the expression level of galectin-3, Eastern Cooperative Oncology Group (ECOG) performance, gender, surgical method, age ≥ 50 years, tumor size, or radiation field were not significant factors. The expression level of galectin-1 affects survival in patients with GBM treated with adjuvant RT. Future studies are required to analyze the effect of other factors, such as O(6)-methylguanine-DNA methyltransferase (MGMT)-promoter methylation status, in patients with weak and strong galectin-1 expression.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 19%
Researcher 5 16%
Student > Ph. D. Student 3 9%
Professor > Associate Professor 3 9%
Student > Doctoral Student 2 6%
Other 1 3%
Unknown 12 38%
Readers by discipline Count As %
Medicine and Dentistry 12 38%
Biochemistry, Genetics and Molecular Biology 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Neuroscience 1 3%
Materials Science 1 3%
Other 0 0%
Unknown 15 47%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2019.
All research outputs
#12,007,640
of 15,742,848 outputs
Outputs from BMC Cancer
#3,420
of 5,868 outputs
Outputs of similar age
#245,150
of 367,503 outputs
Outputs of similar age from BMC Cancer
#2
of 5 outputs
Altmetric has tracked 15,742,848 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,868 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.